W. Satterlee
Impact in
- Psychiatry and Mental health top 1%
- Schizophrenia research and treatment
- Bipolar Disorder and Treatment
- Clinical Biochemistry top 1%
- Bacterial Identification and Susceptibility Testing
Papers in
-
- Electroconvulsive Therapy Studies 4
- Schizophrenia research and treatment 4
- Bipolar Disorder and Treatment 3
- Co-authors
- Charles M. BeasleyP. TranGary D. TollefsonS.H. HamiltonT.M. SangerStephen C. SchimpffArthur A. SerpickViola Mae Young
- Journals
- Schizophrenia Research (3 papers)Investigational New Drugs (2 papers)Journal of Clinical Oncology (2 papers)Radiology (2 papers)European Neuropsychopharmacology (2 papers)
- Partner nations
- United StatesUnited Kingdom
In The Last Decade
W. Satterlee
28 papers receiving 2.5k citations
Hit Papers
Peers
Comparison fields: 5 of 129
- Psychiatry and Mental health 884
- Clinical Biochemistry 285
- Oncology 901
- Biological Psychiatry 64
- Molecular Medicine 109
Countries citing papers authored by W. Satterlee
This map shows the geographic impact of W. Satterlee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Satterlee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Satterlee more than expected).
Fields of papers citing papers by W. Satterlee
This network shows the impact of papers produced by W. Satterlee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Satterlee. The network helps show where W. Satterlee may publish in the future.
Co-authors
The 25 scholars most cited alongside W. Satterlee, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2008 | 50 | |
| 2 | 1997 | 25 | |
| 3 | 1996 | 320 | |
| 4 | Olanzapine versus Placebo and Haloperidol Hit paper breakdown → | 1996 | 643 |
| 5 | 1995 | 2 | |
| 6 | 1995 | 5 | |
| 7 | 1994 | 20 | |
| 8 | 1994 | 7 | |
| 9 | A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. Hit paper breakdown → | 1991 | 661 |
| 10 | 1990 | 2 | |
| 11 | 1990 | 4 | |
| 12 | Kinetics of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641) in humans. | 1990 | 7 |
| 13 | 1989 | 38 | |
| 14 | 1989 | 4 | |
| 15 | 1984 | 69 | |
| 16 | 1984 | 12 | |
| 17 | 1984 | 3 | |
| 18 | 1984 | 98 | |
| 19 | Treatment of malignant pheochromocytoma with a new radiopharmaceutical. | 1983 | 47 |
| 20 | 1967 | 10 |
About W. Satterlee
W. Satterlee is a scholar working on Psychiatry and Mental health, Anesthesiology and Pain Medicine, Pharmacology, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 29 papers that have together received 2.6k indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (5 papers), Medical Imaging Techniques and Applications (4 papers), Electroconvulsive Therapy Studies (4 papers), Schizophrenia research and treatment (4 papers), Neuroblastoma Research and Treatments (3 papers), Pharmacogenetics and Drug Metabolism (3 papers), Bipolar Disorder and Treatment (3 papers) and Treatment of Major Depression (3 papers). The work is most often cited by research in Psychiatry and Mental health (884 citations), Clinical Biochemistry (285 citations), Oncology (901 citations), Biological Psychiatry (64 citations) and Molecular Medicine (109 citations). W. Satterlee has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include Charles M. Beasley, P. Tran, Gary D. Tollefson, S.H. Hamilton, T.M. Sanger, Stephen C. Schimpff, Arthur A. Serpick, Viola Mae Young, Shin Mineishi and Martin N. Raber. Their work appears in journals such as Schizophrenia Research, Investigational New Drugs, Journal of Clinical Oncology, Radiology and European Neuropsychopharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.